NYSE:GKOS

Stock Analysis Report

Executive Summary

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma.

Snowflake

Fundamentals

Flawless balance sheet with reasonable growth potential.


Similar Companies

Share Price & News

How has Glaukos's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0.3%

NYSE:GKOS

0.5%

US Medical Equipment

-0.02%

US Market


1 Year Return

21.2%

NYSE:GKOS

9.9%

US Medical Equipment

1.6%

US Market

GKOS outperformed the Medical Equipment industry which returned 9.7% over the past year.

GKOS outperformed the Market in United States of America which returned 1.9% over the past year.


Share holder returns

GKOSIndustryMarket
7 Day0.3%0.5%-0.02%
30 Day16.3%0.09%2.7%
90 Day-3.2%2.0%1.4%
1 Year21.2%21.2%10.8%9.9%3.8%1.6%
3 Year88.0%88.0%69.0%63.9%45.2%35.8%
5 Yearn/a136.2%109.3%61.8%44.1%

Price Volatility Vs. Market

How volatile is Glaukos's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Glaukos undervalued based on future cash flows and its price relative to the stock market?

14.29x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Glaukos's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).

Glaukos's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).


Price Based on Earnings

Glaukos is loss making, we can't compare its value to the US Medical Equipment industry average.

Glaukos is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Glaukos, we can't assess if its growth is good value.


Price Based on Value of Assets

Glaukos is overvalued based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Glaukos expected to perform in the next 1 to 3 years based on estimates from 8 analysts?

98.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Glaukos's revenue is expected to grow by 19.2% yearly, however this is not considered high growth (20% yearly).

Glaukos's earnings are expected to grow significantly at over 20% yearly.

Glaukos's revenue growth is expected to exceed the United States of America market average.

Glaukos's earnings growth is expected to exceed the United States of America market average.

Glaukos's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Glaukos will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Glaukos performed over the past 5 years?

23.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Glaukos does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.

Unable to compare Glaukos's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Glaukos's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Glaukos has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Glaukos has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Glaukos improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Glaukos's financial position?


Financial Position Analysis

Glaukos is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Glaukos's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Glaukos has no debt.

Glaukos has no debt compared to 5 years ago when it was 551.1%.


Balance Sheet

High level of physical assets or inventory.

Glaukos has no debt, it does not need to be covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Whilst loss making Glaukos has sufficient cash runway for more than 3 years if it maintains the current positive free cash flow level.

Whilst loss making Glaukos has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by -37.6% per year.


Next Steps

Dividend

What is Glaukos's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Glaukos's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Glaukos's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Glaukos has not reported any payouts.

Unable to verify if Glaukos's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Glaukos has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of Glaukos's dividends in 3 years as they are not expected to pay a notable one for United States of America.


Next Steps

Management

What is the CEO of Glaukos's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Thomas Burns (58yo)

17.5yrs

Tenure

US$5,198,717

Compensation

Mr. Thomas William Burns has been the Chief Executive Officer and President at Glaukos Corporation since march 2002. He served as Director of Avedro, Inc. since July 18, 2018 until August 06, 2019. Prior t ...


CEO Compensation Analysis

Thomas's remuneration is about average for companies of similar size in United States of America.

Thomas's compensation has increased whilst company is loss making.


Management Age and Tenure

2.6yrs

Average Tenure

58yo

Average Age

The tenure for the Glaukos management team is about average.


Board Age and Tenure

5.2yrs

Average Tenure

58yo

Average Age

The tenure for the Glaukos board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Recent Insider Transactions

SellUS$2,391,17215 Nov 18
William Link
EntityIndividual
Role
Chairman of the Board
Chairman
Shares41,500
Max PriceUS$58.18

Ownership Breakdown


Management Team

  • Robert Davis (53yo)

    Senior VP

    • Tenure: 4.3yrs
  • Jane Rady (71yo)

    Senior Vice President of Corporate Strategy & Business Development

    • Tenure: 1.4yrs
  • Mory Gharib

    Co-Founder

    • Tenure: 0yrs
  • L. Katz

    Chief Medical Officer

    • Tenure: 2.6yrs
  • Chris Lewis

    Director of Investor Relations

    • Tenure: 0yrs
  • Thomas Burns (58yo)

    CEO, President & Director

    • Tenure: 17.5yrs
    • Compensation: US$5.20m
  • Chris Calcaterra (59yo)

    Chief Operating Officer

    • Tenure: 2.6yrs
    • Compensation: US$1.96m
  • David Haffner

    Senior Vice President of New Technologies

    • Tenure: 2.6yrs
  • Michele Allegretto

    Senior Vice President of Human Resources

    • Tenure: 4.3yrs
  • Joe Gilliam (43yo)

    CFO & Senior VP of Corporate Development

    • Tenure: 2.3yrs
    • Compensation: US$1.95m

Board Members

  • Bill Link (73yo)

    Chairman

    • Tenure: 18.3yrs
    • Compensation: US$264.99k
  • Richard Lindstrom (71yo)

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Aimee Weisner (50yo)

    Director

    • Tenure: 5.2yrs
    • Compensation: US$224.99k
  • Mark Foley (54yo)

    Director

    • Tenure: 5.2yrs
    • Compensation: US$234.99k
  • David Hoffmeister (64yo)

    Director

    • Tenure: 5.2yrs
    • Compensation: US$232.48k
  • Thomas Burns (58yo)

    CEO, President & Director

    • Tenure: 17.5yrs
    • Compensation: US$5.20m
  • Ike Ahmed

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Thomas Samuelson

    Member of Scientific Advisory Board

    • Tenure: 0yrs
  • Marc Stapley (49yo)

    Director

    • Tenure: 5.2yrs
    • Compensation: US$243.99k
  • Rick Lewis

    Member of Scientific Advisory Board

    • Tenure: 0yrs

Company Information

Glaukos Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Glaukos Corporation
  • Ticker: GKOS
  • Exchange: NYSE
  • Founded: 1998
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$2.698b
  • Shares outstanding: 36.83m
  • Website: https://www.glaukos.com

Number of Employees


Location

  • Glaukos Corporation
  • 229 Avenida Fabricante
  • San Clemente
  • California
  • 92672
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GKOSNYSE (New York Stock Exchange)YesCommon StockUSUSDJun 2015
6GJDB (Deutsche Boerse AG)YesCommon StockDEEURJun 2015

Biography

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to tre ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 00:32
End of Day Share Price2019/09/18 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.